https://via.ritzau.dk/rss/releases/latest?lang=da&publisherId=12353927Sidst udsendte pressemeddelelserhttps://via.ritzau.dk/pressemeddelelse/15195798/leo-pharma-presents-new-data-on-delgocitinib-cream-at-eadv-2026-highlighting-real-world-outcomes-in-adults-and-new-adolescent-data-in-chronic-hand-eczema-che?lang=daInterim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3Thu, 01 Oct 2026 10:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15195798/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15196147/leo-pharma-presents-new-tralokinumab-data-at-eadv-2026-highlighting-real-world-outcomes-and-quality-of-life-in-adults-and-adolescents-with-atopic-dermatitis-ad-involving-high-burden-areas?lang=daNew findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5Thu, 01 Oct 2026 08:30:00 GMThttps://via.ritzau.dk/pressemeddelelse/15196147/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15179884/leo-pharma-to-showcase-its-broadest-ever-scientific-program-at-eadv-2026?lang=daLEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.Thu, 24 Sep 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15179884/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15168912/leo-pharma-receives-positive-chmp-opinion-recommending-anzupgor-delgocitinib-cream-for-adolescents-with-moderate-to-severe-chronic-hand-eczema-in-the-eu?lang=daThe Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate. If approved by the European Commission, Anzupgo® would become the first therapy in the EU specifically approved for adolescents with moderate to severe chronic hand eczema, a patient population for whom there are currently no specifically approved treatment options. The positive CHMP opinion is supported by results from DELTA TEEN, a phase 3 trial investigating the efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema.1Fri, 18 Sep 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15168912/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15168872/leo-pharma-announces-fda-acceptance-of-dersimelagon-nda-with-priority-review-and-closes-acquisition-from-tanabe-pharma?lang=daThe U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) date expected by the end of February 2027. LEO Pharma has successfully closed the acquisition of dersimelagon from Tanabe Pharma, strengthening its late-stage pipeline and further leveraging its global dermatology platform. Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor (MC1R) agonist for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic skin diseases with significant unmet medical need.Fri, 18 Sep 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15168872/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15095662/leo-pharma-delivers-10percent-revenue-growth-at-cer-and-strengthens-late-stage-pipeline?lang=daTue, 18 Aug 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15095662/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15095641/leo-pharma-further-strengthens-late-stage-pipeline-with-the-acquisition-of-dersimelagon?lang=daAcquisition adds dersimelagon to LEO Pharma’s rare dermatology pipeline, an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) that has completed Phase 3 development and for which a New Drug Application (NDA) has been submitted to U.S. Food and Drug Administration (FDA) for review in June 2026.1 Leverages LEO Pharma's six decades of dermatology expertise to advance innovation for patients with rare skin diseases through the addition of this oral late-stage asset, building on LEO Pharma’s recent acquisition of Replay and partnership with Boehringer Ingelheim for Spevigo® (spesolimab). EPP and XLP are rare, devastating lifelong genetic disorders that cause severe sunlight-induced skin pain, as well as rash, swelling, redness, burning sensations and, in some cases, liver damage.2,3 Under the terms of the agreement, LEO Pharma will acquire worldwide rights to dersimelagon from Tanabe Pharma for up to USD 435 million in up front and near-term milestone payments together with potential downstream milestones and tiered royalties on net sales.Tue, 18 Aug 2026 06:58:00 GMThttps://via.ritzau.dk/pressemeddelelse/15095641/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15090287/leo-pharma-elects-henriette-mersebach-to-the-board-of-directors?lang=daHenriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the BoardFri, 14 Aug 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15090287/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15042421/leo-pharma-announces-key-results-of-phase-2-trapeds-1-trial-evaluating-pharmacokinetics-and-safety-of-tralokinumab-in-children-with-moderate-to-severe-atopic-dermatitis?lang=daTRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.Thu, 09 Jul 2026 15:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15042421/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/15012614/leo-pharma-to-showcase-new-data-highlighting-the-burden-and-unmet-needs-in-chronic-hand-eczema-at-escd-2026-in-copenhagen?lang=daNew data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2Thu, 25 Jun 2026 11:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/15012614/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14975084/leo-pharmas-net-zero-and-emissions-reduction-targets-validated-by-sbti?lang=daLEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient careMon, 08 Jun 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14975084/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14916681/leo-pharma-lancerer-loqtorzir-toripalimab-pa-hjemmemarkedet-i-danmark?lang=daLOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.Thu, 07 May 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14916681/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14911445/leo-pharma-delivers-9percent-revenue-growth-at-cer-in-q1-2026-and-strengthens-innovation-pipeline?lang=daTue, 05 May 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14911445/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14906695/leo-pharma-bolsters-rare-skin-disease-focus-through-acquisition-of-replay-gene-therapy-platform?lang=daAcquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.Thu, 30 Apr 2026 13:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14906695/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14882356/leo-pharma-expands-its-psoriasis-portfolio-in-china-with-nmpa-approval-of-enstilarr?lang=daNMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3Fri, 17 Apr 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14882356/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14879115/leo-pharma-announces-fda-acceptance-of-supplemental-nda-for-anzupgor-delgocitinib-cream-for-the-treatment-of-chronic-hand-eczema-in-children-aged-12-17?lang=daThe application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).Wed, 15 Apr 2026 12:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14879115/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14846251/leo-pharma-to-present-17-scientific-abstracts-at-aad-2026-highlighting-realworld-evidence-longterm-outcomes-and-patient-experience-across-multiple-dermatological-conditions?lang=daFri, 20 Mar 2026 13:30:00 GMThttps://via.ritzau.dk/pressemeddelelse/14846251/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14802108/leo-pharma-to-nominate-kasper-fangel-as-new-board-member-and-audit-committee-chair?lang=daMon, 23 Feb 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14802108/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14796167/leo-pharma-delivers-10percent-revenue-growth-in-2025-and-more-than-doubles-adjusted-ebitda-margin?lang=daWed, 18 Feb 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14796167/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14760503/leo-pharma-advances-anzupgor-delgocitinib-cream-to-phase-3-trial-in-lichen-sclerosus-ls?lang=daThe phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle.1 The study initiation in LS is part of LEO Pharma's ambition to explore Anzupgo (delgocitinib) creme in additional indications beyond Chronic Hand Eczema (CHE), investigating the potential of delgocitinib as treatment option in skin diseases with high unmet medical need. There are currently no approved treatments specifically indicated for LS in the U.S. or in Europe. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,2,3 making it a potential treatment option for people living with LS disease.Wed, 21 Jan 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14760503/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14742549/leo-pharma-to-present-at-the-44th-annual-jp-morgan-healthcare-conference?lang=daWed, 07 Jan 2026 12:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14742549/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14722113/leo-pharma-appoints-marika-murto-to-lead-global-product-strategy?lang=daMarika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growthTue, 16 Dec 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14722113/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14719531/leo-pharma-submits-adolescent-label-expansion-application-for-anzupgor-to-ema?lang=daLEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.Mon, 15 Dec 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14719531/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14679407/leo-pharma-announces-positive-topline-32-week-key-results-in-adhand-trial?lang=daThe ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.Mon, 17 Nov 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14679407/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14661687/leo-pharma-delivers-8percent-revenue-growth-at-cer-in-9m-2025-and-updates-full-year-outlook?lang=daThu, 06 Nov 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14661687/?publisherId=12353927&lang=dafalse